Does direct-to-consumer advertising affect patients' choice of pain medications?

Current Pain and Headache Reports

Volumn 12, Issue 2, 2008, Pages 89-93

  Liu, Yifei ^b   Doucette, William R ^a  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; ROFECOXIB; SUMATRIPTAN SUCCINATE;

ADVERTIZING; ARTHRITIS; BEHAVIOR; CONSUMER; CONSUMER HEALTH INFORMATION; DIRECT TO CONSUMER ADVERTIZING; DRUG CHOICE; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; INTERNET; INTERPERSONAL COMMUNICATION; MIGRAINE; OSTEOARTHRITIS; PAIN; PATIENT ATTITUDE; PRESCRIPTION; REVIEW; SELF CARE; UNITED STATES;

ADVERTISING AS TOPIC; ANALGESICS; CHOICE BEHAVIOR; DRUG INDUSTRY; HUMANS; MARKETING; PAIN; PHARMACEUTICAL PREPARATIONS;

EID: 42049119156     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-008-0017-2     Document Type: Review

References (34)

1. Draft guidance for industry consumer-directed broadcast advertisements: availability. Fed Regist 1997, 62:43171-43173.
2. IMS Health, Competitive Media Reporting, June 2004. As cited in Vogt DU. Direct-to-consumer advertising of prescription drugs. Washington, DC: Congressional Research Service, Library of Congress; March 25, 2005.
3. Nielson Monitor-Plus: Med Ad News: DTC takes a back seat. Available at: http://www.pharmalive.com/magazines/medad/ view.cfm?articleID=3522. Accessed June 2007.
4. Weissman JS, Blumenthal D, Silk AJ, et al.: Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff 2003, W3:82-95
5. International Association for the Study of Pain: Pain terminology. Available at: http://www.iasp-pain.org. Accessed June 2007.
6. Health, United States, 2006: With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2006.
7. Pain: Current Understanding of Assessment, Management, and Treatments. Reston, VA: National Pharmaceutical Council Inc. and Joint Commission on Accreditation of Healthcare Organizations; 2001.
8. Moncavage M: DTC review today: a changing environment. Presented at FDLI's Advertising and Promotion Conference. September 12, 2002. Available at: http://www.fda.gov/cder/ddmac/presentations.htm. Accessed March 2003.
9. Caudill-Slosberg MA, Schwartz LM, Woloshin S: Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004, 109:514-519.
10. Peck P: Merck issues worldwide recall of Vioxx [press release]. New York: United Press International; September 30, 2004.
11. Prevention: National survey of consumer reactions to direct-to-consumer advertising. Emmaus, PA: Rodale Press; 1998.
12. Time: Consumer and physician attitudes towards direct-to-consumer advertising (consumer survey). New York: Time Inc.; 1998.
13. Prevention: International survey on wellness and consumer reactions to direct-to-consumer advertising of prescription drugs. Emmaus, PA: Rodale Press; 2000.
14. Aikin KJ, Swasy JL, Braman AC: Patient and Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription Drugs: Summary of FDA Survey Research Results. Final Report. Washington, DC: US Food and Drug Administration; 2004.
15. Prevention: Seventh annual survey: consumer reaction to direct-to-consumer advertising of prescription medicines. Emmaus, PA: Rodale Press; 2004.
16. Prescription Drugs and Mass Media Advertising, 2000: A Research Report. Washington, DC: National Institute of Health Care Management Foundation; 2001.
17. IMS Health: Top-line industry data, 2002: leading 20 therapeutic classes by total U.S. dispensed prescriptions, 2002. Available at: http://www.imshealth.com. Accessed March 2003.
18. Liu Y: Patients' Further Drug Information Seeking after Seeing/ Hearing Direct-to-Consumer Advertisements of Prescription Drugs [master's thesis]. Iowa City, IA: University of Iowa; 2004.
19. Bower KN, Frail D, Twohig PL, et al.: What influences seniors' choice of medications for osteoarthritis?: Qualitative inquiry. Can Fam Physician 2006, 52:342-343.
20. Spence MM, Teleki SS, Cheetham TC, et al.: Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005, 62:544-559.
21. Bradford WD, Kleit AN, Nietert PJ, et al.: How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. Health Aff 2006, 25:1371-1377.
22. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages. Consum Rep 2003, 68:33-37.
23. Carbonell M: 10th Annual National Survey on Consumer Reaction to Direct-to-Consumer (DTC) Pharmaceutical Advertising Reveals #1 Action Taken After Seeing DTC Ad: Information Seeking. Available at: http://www.welchmedia.com/news/article_863.shtml. Accessed June 2007.
24. Letter to G.D. Searle & Co. NDA 20-998 Celebrex (celecoxib) capsules, NDA 19-908 Ambien (zolpidem tartrate) tablets MACMIS ID #8518. Washington, DC: US Food and Drug Administration; 2000.
25. Letter to G. D. Searle & Co. NDA 20-998 Celebrex (celecoxib) capsules MACMIS ID #9514. Washington, DC: US Food and Drug Administration; 2000.
26. Letter to Merck & Co Inc. NDA 21-042 Vioxx (rofecoxib) tablets MACMIS ID #9456. Washington, DC: US Food and Drug Administration; 2001.
27. Pfizer pulling ads for Celebrex. Available at: http://money.cnn.com/2004/12/20/news/celebrex/index.htm. Accessed December 2004.
28. Liu Y, Doucette WR, Farris KB, Nayakankuppam D: Drug information seeking intention and behavior after exposure to direct-to-consumer advertisement (DTCA) of prescription drugs. Res Social Adm Pharm 2005, 1:251-269.
29. Prevention: Fifth annual survey: consumer reaction to direct-to-consumer (DTC) advertising of prescription medicines: DTC advertising and self-care, honoring requests for prescription medicines. Emmaus, PA: Rodale Press; 2001.
30. Understanding the Effects of Direct-to-Consumer Prescription Drug Advertising. Melo Park, CA: Kaiser Family Foundation; 2001.
31. Prevention: Year two: a national survey of consumer reactions to direct-to-consumer advertising. Emmaus, PA: Rodale Press; 1999.
32. Bell RA, Kravitz RL, Wilkes MS: Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med 1999, 14:651-657.
33. Berndt ER: The United States' experience with direct-to-consumer advertising of prescription drugs: what have we learned? In Promoting and Coping with Pharmaceutical Innovation: An International Perspective. Edited by Sloan FA, Hsieh C. London: Cambridge University Press; In press.
34. Sheftell F, Dodick D, Cady R: Direct-to-consumer advertising of OTC agents under current FTC regulations: concerns and comment. Headache 2001, 41:534-536.